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ABSTRACT 
 
 
Altered Biomechanical Properties of Large Arteries  
 
in Muscular Dystrophy. (August 2005) 
  
Wendy Watson Dye, B.S., Texas A&M University 
 
Chair of Advisory Committee: Dr. Jay D.  Humphrey 
 
 
Muscular dystrophy is a disease characterized by skeletal muscle weakness and wasting, 
but little is known of alterations in the vascular system that occur with this disease. The culprit in 
many muscular dystrophies is a defective dystrophin-glycoprotein complex (DGC). The DGC is 
a group of transmembrane proteins that connects the cytoskeleton of muscle cells to the 
extracellular matrix; it plays a role in mechanotransduction and the maintenance of structural 
integrity of these cells, and includes the proteins dystrophin and sarcoglycan-delta. The absence 
of these proteins results in severe muscular dystrophies in humans, and thus knockout mice 
lacking the genes encoding for dystrophin (mdx mice) and sarcoglycan-delta (sgcd-/- mice) were 
studied to detect any vascular alterations that occur as a result of a defective DGC.  Acute biaxial 
biomechanical data were obtained through pressure-diameter and axial force-length tests on 
common carotid arteries of mdx, sgcd-/-, and wild-type mice in the active and passive smooth 
muscle state. Functional response to the vasoreactive compounds phenylephrine, 
carbamylcholine chloride, and sodium nitroprusside was also tested. We found significant 
biomechanical differences between the knockout and wild-type mouse arteries: the mdx and 
sgcd-/- arteries had decreased distensibilities in pressure-diameter tests, with mdx arteries also 
having increased circumferential stresses, and the knockout arteries generated increased axial 
loads and stresses in the axial force-length tests. The mdx and sgcd-/- arteries also differed from 
the wild-type in that their ‘homeostatic’ axial stretch, at which the axial force remains constant 
iv 
upon pressurization, was significantly decreased. We conclude that the loss of DGC proteins 
does trigger changes in vascular smooth muscle cells or their interactions with the extracellular 
matrix, yet that the altered vascular system was able to adapt and function without the DGC. 
Knowledge of alterations to the vascular system (and adaptations to these changes) of patients 
with muscular dystrophy could help physicians customize their treatment to extend and enhance 
their lives, especially as medical advances extend the lifespan of these patients and they begin to 
suffer from diseases such as hypertension and atherosclerosis that affect the normal aging 
population. 
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CHAPTER I 
INTRODUCTION 
 
Muscular dystrophies are a broad group of hereditary diseases, characterized primarily 
by progressive muscle weakness and wasting, that affect both humans and animals. One type of 
muscular dystrophy that is both severe and common was named Duchenne’s muscular dystrophy 
(DMD) for one of the physicians who first documented the disease in 1868, Guillame-Benjamin-
Amand Duchenne. This particular disease was, at the time, called “pseudo-hypertrophic 
muscular paralysis” because of the pronounced hypertrophic growth and deterioration of 
function of the lower-limb muscles. The same disease had actually been observed previously and 
described by the English physicians Edward Meryon, William Little, and Richard Partridge as 
well as two Italian physicians, Gaetono Conte and L. Gioja.50 All of the descriptions note that the 
patients presenting with the disease were males (often brothers) under the age of 20 who 
developed enlarged but weakened muscles, especially in their lower extremities, and died very 
young, usually from respiratory failure. Duchenne, who took muscle biopsies from his patients, 
also described the morphology of the disease. He saw that many muscle fibers in affected 
patients were either hypertrophic or atrophic with progressive interstitial fibrosis, showing 
regions of necrosis and regeneration.43 The English neurologist Sir William Richard Gowers took 
a special interest in the disease and offered additional conclusions about pseudo-hypertrophic 
muscular paralysis. He described in detail the unusual way that patients afflicted with the disease 
were able to maneuver themselves into a standing position, which is now called the “Gowers 
sign” and is an easily recognizable characteristic for DMD. Gowers also speculated that the 
disease, manifesting itself predominately in males and often in multiple siblings, was hereditary. 
This thesis follows the style of the Annals of Biomedical Engineering. 
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His series of lectures on the disease included this moving description of pseudo-hypertrophic 
muscular paralysis: and at the 
The disease is one of the most interesting, and at the same time most sad, of all 
those with which we have to deal: interesting on account of its peculiar features 
and mysterious nature; sad on account of our powerlessness to influence its 
course, except in a very slight degree, and on account of the conditions in which 
it occurs. It is a disease of early life and of early growth. Manifesting itself 
commonly at the transition from infancy to childhood, it develops with the 
child’s development, grows with his growth, so that every increase in stature 
means an increase in weakness, and each year takes him a step further on the 
road to a helpless infirmity and in most cases to an early and inevitable death.19 
 
 In later years, physicians began to sort out variations of this disease described by 
Duchenne and Gowers and described them as muscular dystrophies. Becker’s muscular 
dystrophy (BMD) was identified by its similarity but decreased severity to DMD, and different 
forms such as limb-girdle muscular dystrophy (LGMD) and myotonic muscular dystrophy were 
described.52 Techniques in molecular biology refined over the past fifty years enabled scientists 
to locate the DMD gene locus on the short arm of the human X chromosome and clone it without 
knowing the protein product.35 The gene was found to be very large, comprising about 1/1000 of 
the total human genome, and thereby susceptible to spontaneous mutations.37 Then, in 1987, the 
protein product of the known DMD locus was identified and named dystrophin.23 Soon 
thereafter, scientists found that human DMD is caused predominately by deletions in the 
dystrophin gene (although rearrangements and point mutations are also common) that result in a 
truncated and nonfunctional dystrophin protein. The molecular basis of other muscular 
dystrophies, especially those linked to proteins associated with dystrophin in a dystrophin-
glycoprotein complex (DGC), also began to be examined. This complex consists of a series of 
interacting proteins that provides a crucial link between the actin cytoskeleton of muscle cells 
and laminin in the extracellular matrix. The DGC includes dystrophin, the dystroglycans, the 
sarcoglycans, sarcospan, dystrobrevin, and the syntrophins (Figure 1).8 BMD was found to be 
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caused by dystrophin that is either truncated or reduced in amount but still functional, and severe 
forms of LGMD were found to be caused by defects in the sarcoglycan genes. LGMD is 
characterized clinically by symmetrical weakening of the pelvic, scapular, and trunk muscles 
along with elevated serum creatine kinase levels and a degeneration-regeneration muscle cycle; 
this disease can be as devastating as DMD in some cases.13 
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Figure 1: The dystrophin-glycoprotein complex. This group of proteins connects the intracellular 
cytoskeleton of muscle cells to laminin in the extracellular matrix (figure adapted from Cohn and 
Campbell, 2000).8  
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 Researchers simultaneously were analyzing the genome of the mdx mouse, which has an 
X-linked muscular dystrophy and was a potential animal model for DMD. They showed that a 
single point mutation in the murine dystrophin gene, homologous to the human DMD locus, 
causes premature termination of protein translation, resulting in an absence of dystrophin.45 This 
brings us to today, when much of the current research being conducted on DMD now utilizes the 
mdx mouse and other mouse knockout models to assay the consequences of the absence of 
various DGC proteins. 
When referring to the mdx mouse as a model for human DMD, the vast difference in the 
disease phenotype between the mouse and human should be discussed. In people afflicted with 
DMD, muscle cells progressively degenerate and become fibrotic (as collagenous and adipose 
tissue replaces the muscle fibers), 42 and motility and life-span are drastically decreased (most 
patients are wheelchair bound by the age of 11 and do not live beyond the age of 30).23 mdx 
mice, on the other hand, display no overt muscle weakness and have only a slightly reduced life 
span.11 Also, when researchers examined the histopathology of the muscles of mdx mice over 
time, they found that there is a period of muscle degeneration, with invasion of neutrophils and 
macrophages, followed by a period of regeneration in which satellite cells invade and form a 
new population of muscle fibers that have characteristic internal nuclei. For example, 
degenerating fibers were visible in the extensor digitorum longus muscle at 2 weeks of age, but 
the maximum degenerative/regenerative activity occurred at 3-4 weeks. At 12 weeks of age, only 
20% of the fiber area of the muscle was composed of the original fibers. At 26 weeks of age, 
95% of the fiber area was occupied by regenerated fibers with internal nuclei and even so, the 
process of degeneration and regeneration was still occurring.6 A histopathological study later 
verified these results, but showed further that in older mdx mice (12-24 months of age), 
degeneration continues while regeneration declines progressively, resulting in muscle atrophy 
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and fibrosis.39 Systemic serum levels of creatine phosphokinase (CPK), which is an indicator of 
muscular distress, follow a similar time-course. CPK levels increase 10-fold from normal 
baseline levels at 3-5 weeks of age in the mdx mouse and remain elevated until about 29 weeks 
of age, when they normalize.11 
Another characteristic of mdx mouse muscle is the functional compensation of a 
dystrophin-related protein named utrophin. Utrophin has a structure similar to dystrophin, 
lacking a portion of the rod domain but possessing an actin-binding domain on its amino-
terminus and a cysteine-rich domain on its carboxyl-terminus.49 In normal human and mouse 
muscle, this protein is found primarily at the neuromuscular junction. In human DMD and mdx 
mouse muscle, utrophin is not only found throughout the sarcolemma of small-caliber skeletal 
muscles and cardiac muscle, it also associates with the DGC there.31 An interesting finding is 
that utrophin is present in higher concentrations during fetal development of the mdx mouse and 
is reduced to adult levels by the third week after birth. The reduction of utrophin levels coincides 
with the greatest incidence of muscle degeneration, and the regenerating fibers that begin 
appearing label intensely for utrophin.27 An additional finding is that mice genetically altered to 
lack the genes dystrophin and utrophin display a severe muscle wasting phenotype from early in 
life and also have a shortened life span (about 20 weeks). These double knockout mice seem to 
have a disease with symptoms equivalent to human DMD,12 which indicates with the other 
studies that utrophin has a role (perhaps particularly in development) in establishing and 
maintaining functional muscle in the mdx mouse. An extra note is that utrophin was also found 
with immunohistochemistry to be strongly expressed in vascular smooth muscle cells.16 
The mdx mouse is still being used to pursue treatments for DMD such as gene repair, 
stimulation of skeletal muscle regeneration, and replacement with stem cells.5 Research efforts 
are also focused on expanding the body of knowledge on what dystrophin and the DGC actually 
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do in muscle cells. Although it has been studied for nearly 20 years, the exact physiological 
function of the dystrophin protein and the DGC is unknown in any muscle type. 
Some components of the DGC seem to have a primarily structural role in the complex. 
Dystrophin is known to have such a role in establishing the other members of the DGC on the 
muscle membrane. Dystroglycan, a protein product of one gene that is eventually cleaved into  
and  subunits, is the physical connector spanning the membrane of the cell. -dystroglycan 
interacts with dystrophin at its carboxyl-terminus inside the cell, extends across the cellular 
membrane, and binds to -dystroglycan extracellularly.44 -Dystroglycan then binds laminin 
specifically in a calcium- and ionic-dependent manner.14 The dystroglycans are also associated 
with the sarcoglycans,53 which are transmembrane glycoproteins of which there are six different 
types. The combination of sarcoglycan proteins varies for the different muscle types. Skeletal 
and cardiac muscle possess -, -, -, and -sarcoglycan. In the vascular smooth muscle cells, -
sarcoglycan replaces -sarcoglycan (the two are nearly homologous type I transmembrane 
proteins) and -sarcoglycan takes the place of -sarcoglycan (both highly related type II 
transmembrane proteins) while - and -sarcoglycan remain.37 The loss of any of the sarcoglycan 
proteins causes the sarcoglycan subcomplex to be disrupted, with the other three sarcoglycan 
proteins being reduced or absent at the cell membrane.  
Other proteins of the DGC seem to function as signaling rather than structural proteins. 
One such member is syntrophin, a 58-kDa protein with three different isoforms (, 1, and 2) 
that localizes to the carboxyl-terminus of dystrophin.1 Syntrophin has been found to bind to 
dystrobrevin, Grb2, calmodulin, PIP2, and neuronal nitric oxide synthase (nNOS); some of these 
proteins are involved in signaling pathways.4 nNOS is of particular interest in this study, as it is 
part of the DGC in skeletal and vascular smooth muscle where it functions to attenuate 
vasoconstriction of the vascular smooth muscle.47  
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Studies of the consequences of the absence of dystrophin and the DGC have focused on 
two main potential malfunctions. One is the increased susceptibility of skeletal muscle to fatigue 
due to the mechanical strains of muscle contraction (shown in mdx mice).18 The other is a 
disruption of intracellular calcium homeostasis in muscle fibers. One study of dystrophin 
deficient skeletal muscle in mdx mice tried to discern if the primary malfunction in dystrophin-
deficient muscle is the weakness of the sarcolemma or the altered state of the Ca2+ ion channel, 
that is, an increase in membrane permeability to the calcium ion. They postulated that if the 
former is the primary defect, then membrane damage would correlate directly to the magnitude 
of the membrane stress for each contraction. In contrast, if the Ca2+ ion channel state is the 
primary defect, then damage should be due to repeated activation of the muscle that increases 
Ca2+ load.41 One result was that there was no significant difference between the dye-containing 
(indicating damage) muscle fibers in mdx mice in two tests in which identical isometric 
contractions are applied but the number of activations is increased 10-fold in one case. On the 
other hand, there was a significant correlation for both wild-type and mdx mice between the peak 
force (normalized for muscle cross-sectional area) and the percentage of dye-containing fibers. 
The conclusion of the study was that the extent of damage in dystrophic muscle is significantly 
higher for higher amounts of stress, which may overload the regenerative capacity of the muscle 
and leave it permanently injured. In further defense of the conclusion that dystrophin-deficient 
muscle is more susceptible to mechanical damage, it has been found that dystrophin expression 
in healthy skeletal muscle is concentrated at regions known to experience the highest levels of 
axially and radially transmitted mechanical stress, such as the attachment points between the 
sarcolemma and sarcomere.42 It can thereby be postulated that under normal conditions, 
dystrophin and the remainder of the DGC have the primary role of redistributing the mechanical 
stresses involved in contraction throughout the cell and to the extracellular matrix to maintain the 
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structural integrity of muscle cells. This is thought to be accomplished as dystrophin, along with 
intact sarcoglycan and dystroglycan complexes, acts as a link and/or a spring to relieve local 
stresses imposed on cell membranes by distributing them throughout the cell,38 thus protecting 
cells from rupture during repeated contraction and relaxation.20 
The current hypothesis that dystrophin and the DGC have a mechanical role in 
protecting muscle cells from injury during contraction has interesting implications for the 
vascular system of veins, arteries, and capillaries, which is largely composed of smooth muscle 
cells, embedded in an abundant extracellular matrix, that are constantly subjected to axial and 
circumferential stresses and endothelial cells subjected to shear stresses (dystrophin is known to 
be present in both vascular smooth muscle cells and endothelial cells).28 Some observations have 
been made on the state of the vasculature in humans with muscular dystrophies. Early studies of 
DMD outlined a theory of disease progression that involved a defect in the microcirculation, and 
irregularities in the microcirculation have been reported in cases of muscular dystrophy. For 
example, a number of abnormalities were apparent in capillary beds of the biceps brachii of very 
young DMD patients in the preclinical stages of the disease. Electron microscopy revealed 
swollen endothelial cells in ~30% of the small vessels, increased capillary wall and endothelial 
cell areas, and thicker basement membrane around the vessels.33 Also, one study of over 100 
patients undergoing surgery to correct spinal scoliosis included a large subset of young patients 
diagnosed with DMD (n = 48) as well as patients with spinal muscular atrophy and others 
without muscular dystrophy; the study examined the values for estimated blood volume and 
blood loss for the patients during surgery. The estimated blood volumes were similar between 
groups, but the DMD patients had a significantly greater estimated blood loss even though the 
duration of surgery for all groups was similar.36 It has also been reported that human patients 
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with Becker’s muscular dystrophy have a higher local blood flow rate in the tibialis anterior 
muscle than normal subjects, as measured by the 133Xenon clearance method.32  
More recently, it has been shown that mdx mouse arteries do not have a normal response 
to increased flow rates. In one study, isolated carotid and mesenteric arteries were both shown to 
have significantly attenuated vasodilation in response to acute increased flow when compared to 
wild-type arteries.28 The structure of the vessels seemed to be somewhat different also, as the 
wall-to-lumen ratio was significantly increased in mdx arteries and the calculated compliance 
and distensibility were decreased. Yet, in many other aspects there were no significant 
differences between mdx and wild-type arteries, such as diameter changes in response to pressure 
steps (in active and passive smooth muscle states), arterial wall thickness, dilation in response to 
acetylcholine and sodium nitroprusside, contraction in response to calcium, potassium chloride 
(KCl) or phenylephrine, mean arterial pressure, and body weight. A follow-up study29 examined 
the effects of ligations to various branches of the mesenteric arterial system in order to create 
high flow and low flow situations that should force arterial remodeling. It was found that an 
increase in blood flow did not induce outward remodeling in the mdx mesenteric high flow 
arteries as it did in the wild-type mouse. Another result was that endothelial nitric oxide synthase 
(eNOS) expression was not significantly different in high-flow as compared to normal-flow mdx 
arteries, whereas there was a significant increase in eNOS expression between those two groups 
of wild-type arteries. A later study30 showed that arteriolar density measured in the right ventricle 
and in gracilis skeletal muscle is reduced in mdx mice as compared to wild-type. Other vascular 
alterations are present in mice that do not express one of the sarcoglycans, sarcoglycan-delta. 
These sgcd-/- mice have been shown to develop cardiomyopathy as well as irregularities in the 
coronary vessels such as vascular constrictions and reduced lumen size.10  
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In summary, mice with protein deficiencies that disable the DGC, namely the lack of 
dystrophin or sarcoglycan-delta, have abnormalities of their vascular systems and are also 
disease models for the severe human muscular dystrophies DMD/BMD (caused by absent or 
reduced levels of functional dystrophin) and LGMD (caused by the absence of sarcoglycan-
delta). It is therefore constructive to study the vasculature of these mouse models and report any 
abnormalities to equip physicians to effectively treat disorders in patients with DMD, LGMD, 
and other muscular dystrophies. Our research seeks to characterize the inherent biomechanical 
properties of the carotid arteries from mdx and sgcd-/- mice as compared to wild-type mice of the 
same strain. Specifically, we attempted to meet two specific aims. Our first aim was to conduct 
mechanical and functional tests on arteries from the three mouse types in vitro. Our second aim 
was to analyze the unloaded dimensions, pressure-diameter data, force-length data, and axial and 
circumferential stress-strain data from tested arteries (that displayed smooth muscle and 
endothelial function) to make comparisons between mouse genotypes. We also planned to 
preserve tissue from tested and untested arteries in order to conduct RNA and protein analysis. 
The next section of this thesis will describe in detail the fulfillment of these aims that allowed us 
to compare carotid arteries from wild-type, sgcd-/-, and mdx mice to try to determine any 
biomechanical differences that may exist between the three groups.  
The ultimate goal of this study is to equip physicians to effectively treat disorders in 
patients with muscular dystrophy. Current muscular dystrophy research efforts are focused on 
providing a better and longer life for patients with the disease. But, as DMD patients with better 
medical treatment live longer, there is concern that alterations in the vascular system could cause 
individuals with muscular dystrophy to be more susceptible to common vascular diseases such as 
hypertension and atherosclerosis that affect many aging Americans. A better understanding of 
the effect of muscular dystrophy on the vascular system may enable physicians to tailor 
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treatment for muscular dystrophy patients with vascular complications. In addition, our 
examination of the effects of muscular dystrophy on the vascular system will further the body of 
knowledge on the nature and mechanism of the disease. 
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CHAPTER II 
BIOMECHANICAL TESTING TO DEDUCE PROPERTIES OF  
MURINE CAROTID ARTERIES MISSING PROTEINS ASSOCIATED WITH 
MUSCULAR DYSTROPHY 
 
Introduction 
Muscular dystrophy is caused by genetic defects of the components of the dystrophin-
glycoprotein complex (DGC). This complex links the actin cytoskeleton of muscle cells to the 
adjacent extracellular matrix, and is responsible for redistributing stresses on muscle cells to 
maintain structural integrity during contraction and relaxation. The absence of DGC proteins 
could have important implications for the vascular system, which is composed largely of an 
abundant extracellular matrix (ECM) with embedded smooth muscle cells (SMCs) that possess 
the DGC and are constantly subjected to axial and circumferential stresses. It is possible that the 
biomechanical properties of the vasculature are altered in individuals with muscular dystrophies, 
and these alterations could contribute to the progression of the skeletal muscle disease as well as 
cardiovascular, neurovascular, and renovascular diseases.  
 The acute biomechanical and functional properties of dystrophin-deficient (mdx) mice 
and sarcoglycan-delta-deficient (sgcd-/-) mice were compared to those of wild-type controls to 
elucidate any muscular dystrophy-related abnormalities. To this end, a computer-controlled 
perfused organ-culture device15 was used to measure and independently control pressure, axial 
stretch (or force), and luminal flow while measuring the outer diameter of the vessel by 
collecting and processing images from a video-microscope. Values for these and other variables 
were collected at a user-defined rate and written to a computer file for off-line analysis. Analysis 
of the data collected through these methods revealed significant alterations in the carotid arteries  
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of mice lacking proteins associated with severe human muscular dystrophies. 
 
Methods 
Arterial Isolation and Setup in Biaxial Testing Device 
Wild-type and mdx mice were ordered from Jackson Laboratories (Bar Harbor, Maine), 
while breeding pairs of sgcd-/- mice were given by Kevin Campbell (University of Iowa) and 
their offspring used for experiments. All animals were maintained by the Texas A&M University 
Laboratory Animals Resources and Research (LARR) program and were used in accordance 
with the University Lab Animal Care Committee (ULACC) guidelines. Wild-type (n = 6), mdx 
barrier AX6 (n = 5), and sgcd-/- (n = 6) male C57BL/6J mice, between 8 and 12 weeks old, were 
euthanized with a lethal injection of sodium pentobarbital (50mg/kg IP) containing heparin 
(1000-unit/kg IP) and left and right common carotid arteries were isolated. Left arteries were 
placed in warm Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Inc.), supplemented 
with 10% heat-inactivated fetal bovine serum (HI-FBS, Hyclone) as well as 1000 units/L 
penicillin and 1000 g/L streptomycin (P/S, Invitrogen, Inc.), and mounted on perfusion glass 
cannulae at both extremities using 6-0 suture. 
The cannulated left arteries were placed in a bath of fresh, warm DMEM supplemented 
as above within the incubator chamber of the testing device. Flow was initiated intraluminally 
and adventitially from two reservoirs of supplemented DMEM. A load cell was attached to the 
distal cannula and the vessel was imaged. Once an image was obtained, measurements in the 
unloaded configuration (with mean pressure P = 0 mmHg and axial load f = 0 g) were obtained. 
The unloaded diameter D of the vessel was noted, and the overall axial length where the vessel 
just begins to bend was measured as described by Gleason et al.15 and called the unloaded length 
L. After the unloaded configuration measurement, the vessel was stretched axially and 
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pressurized slowly until brought up to in vivo conditions (axial stretch z = 1.8 times the 
unloaded length, P = 100 mmHg, mean intraluminal flow Q = 0.05 ml/min, and temperature T 
between 32-38°C) after which it remained for 30 minutes. After this equilibration period, the 
intraluminal flow was stopped and the vessel was subjected to two cycles of preconditioning, at 
z = 1.95 with P cycled from 0 to 160 mmHg.  
Mechanical and Functional Testing 
Mechanical testing consisted of two parts, pressure-diameter (P-d) and force-length (f-) 
tests. Before the first P-d test, the vessel was depressurized and unloaded to z = 1.0 to verify the 
unloaded length and diameter. If necessary, a new unloaded length was entered at this point and 
the axial load zeroed again; reinitializing the system allowed the remainder of the axial stretch 
data to be based on the new unloaded length. For P-d tests, the vessel was stretched to various 
axial extensions z = 1.60, 1.80, and 1.95 and held while P was cycled from 0 to 160 mmHg. The 
pressure cycle at each stretch was repeated three times. For f- tests, the vessel was maintained at 
pressures of P = 60, 100, and 140 mmHg. As the pressure was held constant, z was decreased 
until the vessel bent and increased up to z = 1.95 twice. At the conclusion of both P-d and f- 
tests, the vessel was depressurized to P = 0 mmHg and unloaded to z  = 1.0; the unloaded values 
L and D were verified, and the axial force value, f, was zeroed again. Lastly, inner and outer 
diameters were measured by manually adjusting video-calipers in the following 10 different 
configurations: P = 0 mmHg and z  = 1.0, 1.2, 1.4 and 1.65; P = 40 and z  = 1.4, 1.65, and 1.8; P 
= 80 mmHg and z  = 1.65 and 1.8; and P = 100 mmHg and z  = 1.8.  
The vessel was then brought up to z =1.65 and P = 80 mmHg (without flow) for 15 
minutes to equilibrate for the function test. At the end of this second equilibration period, the 
adventitial flow was stopped, and 150 µl of a different agonist was added to the bath every 
fifteen minutes. The first agonist was phenylephrine (PE) at a concentration of 10-3 M (which 
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diluted to ~10-5 M in the bath), which tests for contractile ability of the smooth muscle cells. The 
next agonist (after 15 minutes) was carbamylcholine chloride (CCh) at a concentration of 10-3 M 
(which diluted to ~10-5 M in the bath), which tests for endothelial-dependent smooth muscle cell 
relaxation. Next, sodium nitroprusside (SNP) was used at a concentration of 10-2 M (which 
diluted to ~10-4 M in the bath) to induce endothelial-independent smooth muscle dilation. 
Finally, after another 15 minutes, the bath was emptied and refilled with warm Hank’s Balanced 
Salt Solution (HBSS, Invitrogen, Inc.) without calcium and magnesium, but with 2 mM EGTA 
and 10µM SNP to completely relax the smooth muscle cells and the diameter was recorded until 
it stabilized. We conducted the mechanical tests again with the vessel in the calcium-free HBSS 
with EGTA to obtain data in a passive smooth muscle state. The P-d and f- tests were repeated 
as described above, the only difference being that two pressure cycles, instead of three, 
performed at each axial stretch.  
Histochemistry 
After mechanical and functional testing, the left common carotid arteries were unloaded, 
removed from the device, and fixed in 4% paraformaldehyde for 1 hour. The arteries were then 
immersed in a cryoprotectant (30% sucrose) overnight. Next, the arteries were mounted in OCT 
medium (Tissue Tek) in isopentane cooled with liquid nitrogen, stored at -20°C, and cut into 7 
m sections. Sections of tested arteries for each type were therefore available for future 
immunohistochemical analysis. The non-tested, right common carotid arteries for each mouse, as 
well as the thoracic portion of the aorta for a few mice of each genotype, were flash-frozen in 
liquid nitrogen and stored at -80°C until homogenized for future isolation and analysis of RNA 
and protein. 
Data Analysis  
We selected functional vessels for analysis as quantified by at least 30% contraction of  
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the vessel in response to PE (as compared to the final passive diameter of the vessel in 
calcium-free HBSS) and at least 15% dilation (from the contraction caused by PE) in response to 
CCh. Axial force, axial stretch, pressure, and outer diameter data were collected for each vessel 
at 4 Hz during all tests–active and passive mechanical tests and the functional test. The inner and 
outer diameters measured at 10 different configurations allowed us to calculate the volume of the 
vessel wall as 
  λ)( 22 abV −= pi  , (1)  
where a is the inner radius and b the outer radius; the 10 different volume values were averaged 
to give V . Assuming incompressibility, this mean volume and the outer diameter values 
allowed the luminal radius a and wall thickness h to be computed at all states using the following 
formulae: 
   )/(2 λpiVba −= ,   (2)  
   )( abh −= . (3)  
This, in turn, allowed us to calculate the mean axial and circumferential Cauchy stress (z and 	, 
respectively) at every test-point, namely 
  )( 22 ab
f
z
−
=
pi
σ ,  (4)  
   
h
Pa
=ϑσ . (5)  
The axial stretch ratio was calculated as 
  z = /L , (6)  
whereas the circumferential stretch ratio was calculated using mid-wall radii:  
   θ = rmid / Rmid . (7)  
The current mid-wall radius rmid was calculated as  
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  2/)( barmid += , (8) 
while the unloaded mid-wall radius Rmid was calculated as 
   2/)( BARmid +=  (9)  
where B is the outer radius in the unloaded configuration (half of the unloaded diameter D) and 
A can be calculated from wall volume. The inner and outer radii, wall thickness, axial and 
circumferential stresses and stretches can thus be calculated at every test-point using the 
unloaded configuration measured prior to that test. By interpolating between test-points, the 
loaded dimensions, axial force, and axial and circumferential stresses were analyzed using one-
factor analysis of variance (ANOVA) for p < 0.05, with means separation using Bonferroni’s 
post-hoc test. The body weights of the mice as well as the mean wall volumes and unloaded 
dimensions of the arteries were similarly analyzed for p < 0.05. For the P-d test, the outer 
diameter and axial force were compared between pressures of 2 and 140 mmHg, and the 
circumferential stretch was compared for circumferential stretches between 0.5 and 1.4 (these 
ranges of independent variables were common for all vessels of the three genotypes, thus 
enabling statistical comparison). For the f- test, axial force and axial stress were compared from 
the lowest common axial stretch up to an axial stretch of 1.95.  
Another comparison from the f- test was made. It is known that blood vessels are 
extended far beyond their unloaded length in vivo, and also that at the in vivo axial length or 
axial stretch (z in vivo, the in vivo length normalized to the unloaded length) the axial force tends 
to remain constant over a range of pressures.24 One way to discern the in vivo axial stretch of 
arteries already isolated from mice is to examine the results of the force-length curves and find 
the point where the force is the same for different pressures (in our case pressures of 60, 100, and 
140 mmHg). The axial stretch corresponding to this common axial force represents the in vivo 
axial stretch, where the axial force remains relatively constant as the pressure is cycled. We 
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compared the 60, 100, and 140 mmHg force-length curves for each artery to each other to find 
the intersection points between each two curves (which we calculated by interpolating between 
the two closest axial stretch points) and the three intersection points were averaged to yield an 
estimate for that vessels’ in vivo axial stretch z in vivo, and the corresponding axial load fin vivo. We 
also performed ANOVA on those z in vivo values for p < 0.05, with means separation using 
Bonferroni’s post-hoc test. 
The outer diameters measured in response to the various agonists in the functional test 
were normalized to the final passive diameter and compared using ANOVA for p < 0.05, with 
means separation using Bonferroni’s post-hoc test. Comparisons were made between mouse 
genotypes for all data analyses. 
 
Results 
Functional Response  
 Arteries from all three genotypes retained smooth muscle and endothelial function, 
(Table 1). The vessels were partially constricted at the beginning of the test, with diameters that 
were 88% of the final passive diameter for the wild-type group, 86% for the mdx and 85% for 
the sgcd-/-; therefore, the level of vascular basal tone developed was between 12-15%. After 
dosing with PE, the wild-type arteries constricted further to 67% of their final resting diameter, 
the mdx arteries constricted to 66%, and the sgcd-/- constricted significantly more than either the 
mdx or wild-type arteries, to 62% of their final passive diameter. For the remainder of the 
functional test, the three groups of vessels did not display any significant differences in response 
to the agonists. All groups had a similar vasodilatory response to CCh, with the wild-type 
dilating to 84%, and the mdx and sgcd-/- dilating to 82% of their final passive diameter. In 
response to SNP, the wild-type arteries dilated to 97% of their final diameter, whereas the mdx 
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and sgcd-/- dilated to 95%. When the media was changed to the calcium-free salt solution with 
EGTA, the arteries dilated slightly to reach their final passive diameter. Figure 2 shows the 
representative functional behavior of one vessel from each mouse type. 
Mechanical Response  
 The general mechanical response of these three groups of mouse carotid arteries to 
biaxial testing was similar to that reported for other mouse carotids tested in our lab (FVB/N)15 
and elsewhere (C57-B110)28 . In the pressure diameter tests, the arteries distended substantially 
in response to increasing pressure, but began stiffening at higher pressures. The sudden 
stiffening was more apparent in the passive testing, as the active P-d curves displayed a more 
linear response due to the influence of smooth muscle cell contraction. Vessels of the three 
mouse groups responded similarly for pressure cycles at the low (z =1.65) and mid (z =1.80) 
axial stretches; there were no significant differences between either the mdx or sgcd-/- and wild- 
type outer diameters at these axial stretches. Differences between groups were accentuated at the 
high (z =1.95) axial stretch and mid-to-high pressures (Figure 3) as the diameters were 
significantly smaller in the active and passive tests for both mdx and sgcd-/- compared to the 
wild-type. The axial forces required to maintain a constant axial stretch during the P-d test were 
similar for all three mouse groups at the low axial stretch of 1.65. At the mid stretch of 1.80, 
however, the mdx axial force values were significantly greater at the high pressures. At the high 
stretch of 1.95, the mdx axial force values were significantly greater for the whole pressure 
range, while the sgcd-/- values were greater only at high pressures. The circumferential stress-
strain data showed that only mdx stresses were significantly different from those of the other 
mouse types. The mdx circumferential stress 	 values were significantly increased compared to 
the wild-type stresses for a small range of circumferential stresses for the low and mid axial  
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Table 1: Comparison of mouse and vessel properties for  
wild-type, mdx, and sgcd-/- mice 
------26.7   1.0129.1   1.20
Animal Properties a
27.3   1.01Body Weight (g)
62.9   263.6   363.3   372.2   371.5   3
145   6152   6148   6119   6131   6
416   10432   11424   10383   10406   11
Unloaded dimensions d
392   10OD (m)
123   6A (m)
72.7   3H (m)
1.73   0.02*1.72   0.02*1.84   0.02 1.78   0.02*1.74   0.02*
------0.331   0.030.360   0.03
Vessel Properties
0.338   0.03V (mm3) b
1.88   0.02 z in vivo c
Functional response e
------0.854   0.02 0.861   0.020.881   0.02Basal Tone
------0.617   0.01*0.660   0.010.666   0.01Contraction to PE
------0.821   0.020.820   0.020.844   0.02Dilation to CCh
------0.947   0.010.953   0.010.974   0.01Dilation to SNP
sgcd-/-mdxWild-typesgcd-/-mdxWild-type
PASSIVEACTIVE
   
     
     
      
 
 
     
   
 
   
   
   
   
 
 
All data are represented as mean ± s.e.m., and a * indicates statistical significance when either the mdx or sgcd-/- 
value is compared to the wild-type (p < 0.05 with Bonferonni’s post-hoc test for means separation). 
a
 These values are the average body weights of mice tested for each mouse type. No significant differences were 
found. 
b
 These values are the calculated mean volumes of the vessels tested for each mouse type. 
c
 This set of data is the mean in vivo axial stretches (z in vivo) inferred from axial force-length active and passive testing 
for each mouse type. 
d  These values are the mean unloaded outer diameters (OD), inner radii (A), and wall thicknesses (H) for each mouse 
type measured at the start of the active and passive mechanical tests. 
e
 This set of data is from the function test results and shows outer diameters in response to agonists normalized to the 
final, most dilated diameter of the vessel in response to calcium-free HBSS with EGTA and SNP. The first row of 
values was measured after equilibration to testing conditions (Basal tone), the second after contraction to 
phenylephrine (PE), the third after dilation to carbamylcholine chloride (CCh), and the fourth after dilation to sodium 
nitroprusside (SNP). 
 
21 
 
Wild-type
11/05/04
mdx
01/25/05
sgcd-/-
11/17/04
Time (minutes)
D
ia
m
et
er
 
(
m
)
300
500
600
700
400
0 10 20 30 40 50 60
CCh
PE
Ca2+ free HBSS 
+ EDTA
SNP
D
ia
m
et
er
 
(
m
)
 
Figure 2: Representative functional response of vessels of all three mouse types. The change in outer 
diameter in response to agonists of a wild-type vessel tested 11/05/04, an mdx vessel tested 1/25/05, and a 
sgcd-/- vessel tested 11/17/05 are graphed over time. Phenylephrine (PE) was used to test for smooth 
muscle contraction, carbamylcholine chloride (CCh) was used to test for endothelial-dependent smooth 
muscle dilation, and sodium nitroprusside (SNP) was used to test for endothelial-independent smooth 
muscle dilation. Calcium-free salt solution (HBSS) with a calcium chelator (EGTA) was used to relax the 
smooth muscle cells completely. 
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Figure 3: Active (basal tone) and passive (Ca2+ free) P-d curves at the high (z =1.95) axial stretch 
setpoint. Note that the diameters for the mdx and sgcd-/- tend to be smaller. The mdx values become 
significantly different (p < 0.05) from the wild-type over the pressure range P = 92 – 140 in the active 
state and at P = 66 – 140 in the passive state (indicated by the *M). The sgcd-/- values are significantly 
different for the pressure range P = 102 – 140 in the active state and P = 74 – 140 in the passive state 
(indicated by the *S). 
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stretches, and over a broader range at the high axial stretch. Figure 4 shows the circumferential 
stress-strain behavior at the high axial stretch, in which there is also a range of circumferential 
stretches in both the active and passive states at which the mdx circumferential stress was 
significantly greater than the sgcd-/- circumferential stress. 
 One interesting finding was that the axial force response at the high axial stretch of 1.95 
for the wild-type was fairly constant; in contrast, the axial force for mdx and sgcd-/- vessels 
increased greatly. At the mid axial stretch, the mdx and sgcd-/- axial force responses were 
constant, whereas the wild-type axial force decreased at the mid to high pressures. When we 
compared all the axial force responses during pressurization for the three mouse groups at the 
three axial stretches, as in Figure 5, it seemed that the wild-type force response at the high axial 
stretch of 1.95 was similar to the mdx and sgcd-/- force responses at the mid axial stretch of 1.80. 
Because the axial force remains constant over a range of pressures when the axial stretch is near 
the in vivo value,24 whereas the axial force increases at axial stretches greater than the in vivo and 
decreases at axial stretches less than the in vivo axial stretch, we can infer that the in vivo axial 
stretch of the carotid artery for the wild-type is greater (z  1.95) than that for the mdx and  
sgcd-/- mouse groups (z  1.80).  
 Results for the axial force-length test showed significant differences between the mouse 
groups occurring predominately at the high pressure of 140 mmHg and high axial stretches. The 
axial force corresponding to axial stretches for the mdx and sgcd-/- vessels were not significantly 
greater than the wild-type at the low pressure of 60 mmHg, except that the mdx value at very 
high axial stretches was significantly greater than that for the wild-type in the active and passive 
tests. At the mid pressure of 100 mmHg, the mdx and sgcd-/- axial forces were significantly 
higher than those for the wild-type for a range of high axial stretches in the active and passive  
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*M-S*M-S
Figure 4: Active (basal tone) and passive (Ca2+ free) circumferential stress-stretch curves at the high (z = 
1.95) axial stretch setpoint. There were two ranges of circumferential stretch values in the active state (	 = 
0.740 – 1.280, 1.370 – 1.400) and one range in the passive state (	 = 0.860 – 1.145), indicated by *M, for 
which the mdx circumferential stresses were significantly greater (p < 0.05) than the wild-type values. 
There is also a range of in the active (0.905 – 0.950) and passive (0.890 – 0.920) state for which the mdx 
stresses were significantly greater than the sgcd-/- stresses, indicated by *M-S. Although there are visible 
trends in the data, the variance of the stresses at the high stretch values prevented statistical differences 
from being reported over a wider range of values. 
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Figure 5: Active axial force response during P-d test for all mouse groups at all axial stretch setpoints. 
Mouse type (wt = wild-type) and axial stretch are indicated on the right axis where the curve ends. Note 
the similarity between the wild-type curve at the high axial stretch (z =1.95) and the mdx and sgcd-/- 
curves at the mid axial stretch (z =1.8). 
 
 
 
 
 
states. At the high pressure of 140mmHg, the mdx and sgcd-/- axial force values were  
significantly higher than the wild-type at mid-range axial stretches in the active and passive 
states.  
 The axial stress-stretch data were similar to the axial force-length data despite subtle 
differences. There were few significant differences between groups in the axial stress-stretch 
data at the low pressure for the active test. At the mid pressure, there were significant differences 
between both sgcd-/- and mdx values as compared to the wild-type, with a larger range of 
significant differences in the passive than the active state. At the high pressure, there was a broad 
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range of axial stretches for both mdx and sgcd-/- at which the axial stresses were significantly 
higher than the wild-type (Figure 6). These differences were again more pronounced in the 
passive test. Table 2 shows the ranges at which results for the various mechanical tests were 
statistically different between mouse types.  
 We estimated the in vivo axial stretch (z in vivo) by calculating the intersection point 
between the three force-length curves for each vessel, (measured at the low, mid, and high P set- 
points as shown in Figure 7) and found that the wild-type vessels had a significantly higher in 
vivo axial stretch as compared to mdx and sgcd-/-. The axial load required to maintain the in vivo 
axial stretch was significantly lower for mdx and sgcd-/- vessels than for the wild-type. The 
average passive and active in vivo axial stretches and corresponding axial loads for the three 
types are shown in Figure 8. The values for the passive and active in vivo axial stretches z in vivo 
were also included in Table 1 with the average unloaded dimensions of the vessels for each 
mouse type. 
Normalization to in vivo Axial Stretch  
 With the observation concerning the axial force-pressure data, that is, that the wild-type 
curve for the high axial stretch looked similar to the mdx and sgcd-/- curves for the mid axial 
stretch, additional comparisons were warranted. For the P-d test, we calculated the stretch ratio  

 = z / z in vivo for the high (z = 1.95), mid (z = 1.80), and low (z = 1.65) axial stretches used in 
testing and for the estimated in vivo axial stretch of each mouse type. We found that for the 
active and passive P-d tests, the wild-type vessels experienced a small 
 at the high axial stretch 
(~1.03 for the active and ~1.06 for the passive) which was very close to that experienced by the 
mdx (~1.03 active, ~1.05 passive) and sgcd-/- (~1.01 active, ~1.04 passive) vessels at the mid 
axial stretch. That is, the mdx and sgcd-/- vessels experienced a small amount of axial stretch, 
relative to the axial stretch they feel in vivo, when P-d tests were conducted at the mid axial  
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Figure 6: Active (basal tone) and passive (Ca2+ free) axial stress-stretch curves at the high (P = 140 
mmHg) pressure setpoint. The axial stresses for the mdx and sgcd-/- tend to be greater than the wild-type 
over wide ranges in both the active and passive states. The mdx values become significantly different (p < 
0.05) from the wild-type over the axial extension range z = 1.77– 1.95 in the active state and at z = 1.83 – 
1.95 in the passive state (indicated by the *M). The sgcd-/- values are significantly different for the 
pressure range z = 1.83 – 1.95 in the active state and z = 1.77 – 1.95 in the passive state (indicated by the 
*S). 
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Table 2: Summary of significant differences for mechanical tests 
Range of 
values on 
which 
ANOVA was 
performed
Range of values over which statistical significance (p < 0.05) was observed
Testing P = 140mmHg
Testing P = 100mmHg
Testing P  =  60mmHg
Axial stress-stretch e
Testing P = 140mmHg
Testing P = 100mmHg
Testing P  =  60mmHg 
Axial force-length d
Testing  z = 1.95
Testing  z = 1.80
Testing  z = 1.65
Circumferential  
stress-stretch c
Testing  z = 1.95
Testing  z = 1.80
Testing  z = 1.65
Force-pressure b
Testing  z = 1.95
Testing  z = 1.80
Testing  z = 1.65
Diameter-pressure a
1.11–1.95
1.11–1.95
1.11–1.95
over  z
1.11–1.95
1.11–1.95
1.11–1.95
over  z
0.500–1.400
0.500–1.400
0.500–1.400
over 
2–140
2–140
2–140
over P
2–140
2–140
2–140
over P
Axial force
Axial stress
Outer diameter
NSNS1.010–1.115NSNSNS
NSNS0.980–1.040NSNS0.935–1.025
0.890–
0.920NS0.860–1.145
0.905–
0.950NS
0.740–1.280, 
1.370–1.400
1.83–1.95
1.93–1.95
NS
1.81–1.95
1.91–1.95
NS
82–140
NS
NS
102–140
NS
NS
sgcd -/-
versus 
wt
1.77–1.95
1.89–1.95
NS
1.75–1.95
1.85–1.95
1.95
Axial force
Circumferential stress
2–140
120–140
NS
92–140
NS
NS
mdx 
versus 
wt
ACTIVE
1.71–1.95
1.77–1.95
1.95
1.73–1.95
1.77–1.95
1.91–1.95
50–140
86–140
128–140
66–140
NS
NS
mdx 
versus
wt
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
mdx 
versus 
sgcd -/-
NSNS
NSNS
NS74–140
NSNS
NS110–140
NS54–140
PASSIVE
NS1.77–1.95
NS1.83–1.95
NSNS
NS1.77–1.95
NS1.83–1.95
NSNS
mdx 
versus  
sgcd -/-
sgcd -/-
versus 
wt











 
 
 
Data shown are ranges of statistical significance (p < 0.05 with Bonferonni’s post-hoc test for means separation) for 
various mechanical tests in the active and passive states for the different comparisons between mouse types, that is, for 
mdx versus wild-type (wt), sgcd-/- versus wild-type (wt), and mdx versus sgcd-/-. “NS” indicates no significant 
differences for that test for the different comparisons between mouse types. 
a
 This set of data is for the pressure-diameter results and shows the pressure range over which outer diameters were 
significantly different.  
b This set of data is for the pressure-force results and shows the pressure range over which axial forces were 
significantly different. 
c This set of data is for the circumferential stretch-stress results and shows the circumferential stretch range over which 
circumferential stresses were significantly different. 
d This set of data is for the axial force-length results and shows the axial stretch range over which axial forces were 
significantly different. 
e
 This set of data is for the axial stretch-stress results and shows the axial stretch range over which axial stresses were 
significantly different. 
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Figure 7: Estimation of the in vivo axial stretch (z in vivo). We calculated the intersection point between the 
three force-length curves for each vessel, (measured at the low, mid, and high P set- points) to estimate the 
in vivo axial stretch, the axial stretch at which the axial load remains constant over pressure, and the 
corresponding in vivo axial load sustained at that axial stretch for each mouse type.  
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Figure 8: Average axial stretch z and axial force values (with standard errors) at which the average axial 
f- curves for each mouse type, measured at three different pressure setpoints, intersect in the active (basal 
tone) and passive (Ca2+ free) states. This intersection point between f- curves represents the in vivo axial 
stretch, at which the axial load remains constant for any pressure. A * indicates significant differences of 
the mdx and sgcd-/- values from the wild-type (p < 0.05) with Bonferonni’s test for means separation.  
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stretch. The wild-type vessels experienced a similar small amount of stretch beyond their in vivo 
axial stretch at the high axial stretch used for P-d tests. We then compared the wild-type outer  
diameters at the high axial stretch of 1.95 to the mdx and sgcd-/- values at the mid axial stretch of 
1.8 and found that no significant differences (p < 0.05) were present in either the active or 
passive tests (Figure 9). There were also no significant differences between the circumferential 
stress-stretch data measured at the high axial stretch for the wild-type and the mid axial stretch 
for the mdx and sgcd-/- values (Figure 10). 
 Finally, for the f- test, we again calculated the stretch ratio 
 by normalizing all 
measured axial stretches z to the in vivo axial stretches (z in vivo) estimated for each mouse type. 
Then we compared the axial loads and stresses to common values of the stretch ratio 
. We 
found that this way of comparing the data reduced the number of significant differences between 
the wild-type and the mdx and sgcd-/- vessels. For tests in active or passive states at the high 
pressure of 140 mmHg, there were no significant differences between mouse types in the axial 
load or axial stress once we took the in vivo axial stretch into account (Figure 11). At the 
pressures of 60 and 100 mmHg, there were also no significant differences between the sgcd-/- 
and wild-type for axial load or axial stress values. Indeed, there were only significant differences 
between the mdx and wild-type over a small range of stretches at the mid pressure and over a 
larger range of stretches at the low pressure for both the axial load and axial stress. 
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Figure 9: Active (basal tone) and passive (Ca2+ free) P-d curves at the high (z = 1.95) axial stretch 
setpoint for the wild-type and at the mid (z = 1.80) axial stretch setpoint for the mdx and sgcd-/- arteries. 
Comparing the results from these two different axial stretch setpoints allows us to see the change in 
diameter over pressurization for all three groups of vessels when stretched to ~1.05 of their in vivo axial 
stretch. The diameter values for the mdx and sgcd-/- are no longer significantly different from the wild-
type in either the active or passive state (p < 0.05) when the estimated in vivo axial stretch is taken into 
account for each mouse type. 
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Figure 10: Active (basal tone) and passive (Ca2+ free) circumferential stress-stretch curves at the high (z 
= 1.95) axial stretch setpoint for the wild-type and at the mid (z = 1.80) axial stretch setpoint for the mdx 
and sgcd-/-arteries. Comparing the results from these two different axial stretch setpoints allows us to 
compare the three groups of vessels when stretched to ~1.05 of their in vivo axial stretch. Note that when 
the axial stretch is normalized to the estimated in vivo axial stretch for each mouse type, the 
circumferential stresses for the mdx and sgcd-/- are no longer significantly different from the wild-type in 
either the active and passive state (p < 0.05).  
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Figure 11: Active (basal tone) and passive (Ca2+ free) axial stress-stretch curves, with the axial stretch 
normalized to the in vivo axial stretch, at the high (P = 140mmHg) pressure setpoint. Note that when the 
axial stretch is normalized to the estimated in vivo axial stretch for each mouse type, the axial stresses for 
the mdx and sgcd-/- are no longer significantly different from the wild-type in either the active and passive 
state (p < 0.05)  
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Discussion 
 We found biomechanical differences between large arteries of mdx mice lacking 
dystrophin (as occurs in the human disease Duchenne’s muscular dystrophy) and sgcd-/- mice 
lacking sarcoglycan-delta (as in human limb-girdle muscular dystrophy) when compared to wild-
type controls. Specifically, mdx and sgcd-/- carotid arteries did not distend as much as wild-type 
arteries, and mdx arteries exhibited increased circumferential mean stresses in pressure-diameter 
testing. Also, mdx and sgcd-/- arteries exhibited higher axial forces and mean axial stresses, as 
compared to wild-type arteries, during axial force-length testing. The pressure-diameter testing 
also showed that the axial force required to maintain a constant stretch was greater for mdx and 
sgcd-/- arteries than for wild-type arteries at mid and high axial stretches. These differences were 
present in both active and passive SMC states, although the functional response and unloaded 
dimensions of mdx, sgcd-/-, and wild-type arteries were similar. 
 One way to explain the mechanical behaviors of the mdx and sgcd-/- arteries involves a 
shift in the phenotype of the vascular SMCs in these arteries from the differentiated, contractile 
phenotype to the dedifferentiated, synthetic phenotype. The phenotype of vascular SMCs is 
intimately associated with the extracellular matrix (e.g., laminin, fibronectin, elastin, collagen, 
and glycosaminoglycans) that surrounds the cells.24 Linkages between the vascular SMCs and 
the extracellular matrix are made by transmembrane proteins, namely integrins, but also through 
syndecans, cell adhesion molecules (CAMs), and the DGC.34 -Dystroglycan is the specific 
extracellular component of the DGC that connects muscle cells to the extracellular matrix by 
binding to laminin. Laminin binding to vascular SMCs signals the cells to take on the contractile 
phenotype, as characterized by expression of -smooth muscle actin and the presence of 
structural myofilaments.48,21 Fibronectin binding, on the other hand, seems to be involved in 
dedifferentiation of vascular SMCs to the synthetic phenotype and is associated with early 
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development and injury to the vascular system.48 A normal part of development for muscle cells 
is a switch in phenotype from synthetic and proliferative to contractile that begins to occur just 
prior to birth (>80% of SMCs are actively replicating) and continues through early postnatal life 
(~40% SMC replication) until the majority of SMCs are differentiated and contractile in 
adulthood (<0.06% SMC replication).26, 46 It may be that in development of arteries lacking a 
functional DGC, the link between vascular SMCs and laminin that stimulates differentiation is 
made incompletely or is delayed, while fibronectin linkages continue to stimulate synthetic 
activity. Changes in vascular SMC linkages to the ECM could be effected by integrins, which 
are heterodimeric, transmembrane proteins with paired  and  subunits and ligand-binding 
specificity. Abnormal expression of integrins occurs when the DGC is absent. Specifically, 71 
is upregulated in muscle of mdx and sgcd-/- mice2 as well as in DMD patients.22 71 links the 
cytoskeleton of muscle cells to laminin, and may partly compensate for the lack of laminin 
binding in the absence of an intact DGC. Yet, 51 is also increased in mdx and sgcd-/- mice. 
This integrin is a major fibronectin linkage for myofibers and was found in conjunction with 
fibrosis and regenerating skeletal muscle fibers.2 The increase of both 71 and 51 integrins 
may represent two groups of vascular SMCs, some that form a laminin connection via integrins 
in the absence of the DGC to establish the contractile phenotype and others that instead link to 
fibronectin and maintain a synthetic phenotype. It has been noted that heterogeneity of SMC 
phenotype is characteristic in normal vascular tissue, and that this cellular diversity equips the 
blood vessel to maintain vascular homeostasis in normal or pathologic conditions.46 But, perhaps 
in the mdx and sgcd-/- arteries the fine balance of contractile and synthetic SMCs is perturbed 
when binding to laminin via the DGC is compromised. Through increased binding to fibronectin, 
more vascular SMCs may remain in the synthetic phenotype and secrete ECM components such 
as collagen I and III. In fact, the abnormal deposition by muscle cells of collagen to the extra-
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cellular matrix, which results in fibrosis, is a hallmark of muscular dystrophy.3 An 
overabundance of these structural proteins in the arteries of mdx and sgcd-/- mice could explain 
the altered mechanical properties that we observed. It may be possible to measure a collagen 
mass fraction from frozen sections taken from wild-type, mdx, and sgcd-/- carotid arteries to 
quantify any changes in the amount of collagen present in the ECM.  
 A secondary explanation for the upregulation of 51 in mdx and sgcd-/- mice is that its 
heightened levels represent muscle regeneration, as this integrin is present in developing 
myofibers. Muscle degeneration and regeneration is characteristic of muscular dystrophy in 
humans and animals, and occurs in skeletal muscle of mdx mice.40 Indeed, mdx mice have the 
capacity to regenerate sufficient amounts of functional muscle and display a much milder disease 
phenotype, characterized by a normal life-span with no overt muscle weakness, than that of 
DMD.6 Perhaps the vascular SMCs that are not able to compensate for the loss of the DGC 
linkage suffer necrosis, but proliferation of the healthy SMCs replaces the damaged and dying 
muscle cells. The developing vascular SMCs may thus be able to forge a link to laminin through 
71 or by upregulating utrophin, a protein with binding domains that are remarkably similar to 
dystrophin. If utrophin expression is high enough, it can take the place of dystrophin in 
associating with the DGC,31 and utrophin expression is high in regenerating mdx muscle fibers.27 
Utrophin replacement of dystrophin in regenerating fibers of mdx mice may be partially 
responsible for the mild disease phenotype, as supported by the fact that dystrophin/utrophin 
deficient mice display an early onset of muscular dystrophy and die prematurely, similar to 
patients with DMD.12 Although utrophin activity could change the mechanical properties of the 
arteries in mdx mice by replacing dystrophin, it should not change the state of the DGC in sgcd-/- 
mice that possess functional dystrophin. Yet, our results showed remarkably similar mechanical 
behavior between arteries of mice missing dystrophin and the arteries of mice lacking 
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sarcoglycan-delta but possessing dystrophin, suggesting that the absence of an intact and 
functional DGC in both mouse types is responsible for the changes in mechanical behavior. An 
assay to determine the expression of proteins such as utrophin and the integrins 51 and 71 
integrins in the mdx and sgcd-/- vascular smooth muscle is needed before any conclusions can be 
made. 
 This leads us to another explanation of our results involving the significant increases in 
axial force exerted during P-d testing by the sgcd-/- and mdx arteries. We investigated this result 
further by calculating an estimate of the in vivo axial stretch ratio by finding the intersection of 
the axial f- curves taken at different pressure setpoints (expecting that at the in vivo axial 
stretch, the axial force needed to maintain the stretch will remain fairly constant over a range of 
pressures). The estimates for the in vivo axial stretch suggested that mdx and sgcd-/- carotid 
arteries had a reduced in vivo axial stretch ratio compared to wild-type arteries. Although we did 
not measure the axial stretch of the mouse arteries in vivo and ex vivo to confirm the difference 
in the in vivo axial stretch ratio between the knockouts and the wild-type, our mechanical data 
suggested strongly that there was a true difference between the wild-type and knockout mice. 
We normalized our raw data using calculated estimates of the in vivo axial stretch ratio for all 
three mouse types, and found that this drastically reduced the significant differences we had 
seen. In particular, there were no longer differences between mdx or sgcd-/- and wild-type outer 
diameter values and circumferential stresses measured in the P-d test or axial forces and stresses 
measured in the f- test. The only significant differences that persisted were decreased axial 
forces during pressurization in active and passive P-d tests for the mdx arteries compared to 
wild-type. It seems that mdx and sgcd-/- arteries have somehow decreased their in vivo axial 
stretch to a level at which their response to mechanical stimuli is nearly identical to the arteries 
of normal, wild-type mice. 
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 These results reaffirm that axial stress is an important factor driving vascular remodeling 
of large arteries, although it has been little studied in comparison to hoop stress and shear stress, 
two other factors that also play a role in remodeling. Axial, or longitudinal, forces are imposed 
on arteries by connections to peri-arterial tissues and result in axial stretches, which are 
displayed in the retraction blood vessels undergo when isolated from the rest of the vascular 
system. Studies conducted on vascular remodeling caused by changes in axial stretch (and 
thereby axial force) have shown that increases in axial tension can be normalized rapidly by 
smooth muscle cell growth and remodeling without the loss of vascular function. Mouse carotid 
arteries cultured at axial stretches greater or less than their in vivo axial stretch exhibited changes 
in their force-pressure character, probably by reorientation of SMCs, to approximate the in vivo 
character in only two days.16 Axial stretch increases of 50% of rabbit carotid arteries in vivo were 
normalized in one week as, through SMC and extracellular matrix (ECM) proliferation, the 
vessel “grew to a new length”.25,17 Porcine carotid arteries stretched incrementally to ~50% of 
their physiological axial length over 9 days in culture were found, upon removal from the 
system, to be lengthened 20% as compared to their initial unloaded configuration.7 The increased 
axial stretches imposed on the vessels in these studies had the effect of increasing the axial force 
f
 
and thereby the axial stress z; these increases were sensed by vascular SMCs and normalized 
by growth and rearrangement of the cells and the surrounding ECM. 
 Why do mdx and sgcd-/- mouse carotid arteries adopt a decreased in vivo axial stretch, at 
which the axial load is maintained constant over a range of pressures, as compared to the wild-
type? It seems that the mdx and sgcd-/- arteries have adapted to a decreased axial stretch at 
which they were able to respond to imposed mechanical stresses the way wild-type arteries did at 
an increased in vivo axial stretch. We can postulate that this decreased axial stretch was 
established in mdx and sgcd-/- mice in vivo through development to compensate for the 
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important DGC transmembrane link to the ECM that is absent in these SMCs. It may be that for 
the mdx and sgcd-/- arteries, the axial tension felt by the SMCs is increased in the absence of an 
intact DGC, which is thought to redistribute local mechanical stresses imposed on the muscle 
cell membranes throughout the cell cytoskeleton and to the extracellular matrix, thus protecting 
the cell membrane from damage.38 Without the link the DGC provides between the SMC 
cytoskeleton and the ECM, the SMCs may not be able to bear the axial stresses imposed on them 
and they begin to reorient, grow and/or proliferate to lengthen the vessel and thereby attenuate 
the axial stresses on the SMCs, as in the stretch studies mentioned earlier. Part of this 
lengthening process may be hypertrophy of the circumferentially oriented SMCs, which 
correlates well with the hypertrophy of skeletal muscle fibers that is characteristic of muscular 
dystrophy and occurs in young mdx mice.39 At the new, decreased axial stretch to which the 
vascular SMCs adapt the vessel, the corresponding average axial load exerted by the vessel is 
decreased (Figure 8). Figure 12 demonstrates that the mdx and sgcd-/- vessels have slightly 
reduced the axial load they must exert to maintain their reduced in vivo axial stretch over a range 
of pressures. It seems that there has been a remodeling event, changing the state of the vascular 
SMCs and the ECM (as evidenced by changes in the active and passive smooth muscle state), to 
decrease the axial loads and stresses imposed on the system to tolerable levels in carotid arteries 
of mdx and sgcd-/- mice. Notably, the mdx and sgcd-/- arteries do not seem to have remodeled in 
response to changed circumferential or shear stresses, as the wall thicknesses and inner and outer 
diameters in the unloaded and loaded states were not significantly different from the wild-type. 
This distinguishes the remodeling we observed from that reported in hypertension, in which 
decreases of the in vivo axial stretch of aortic segments were accompanied by increases in the 
wall thickness and mid-wall radius.51 It seems that the vessel growth and remodeling in the 
arteries of mdx and sgcd-/- mice occurred solely to reduce the axial force, and thereby the axial 
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stress, while maintaining the levels of the other stresses. The vessel therefore lengthened and 
changed the value of the axial stretch without thickening its wall or growing inward or outward, 
thereby holding constant the values for wall thickness and inner and outer diameter and 
maintaining the levels of shear stress and circumferential stress on the vascular SMCs. Culturing 
the mdx and sgcd-/- mouse carotid arteries at axial stretch ratios different than the estimated in 
vivo value could elucidate the remodeling process that occurs in the absence of the DGC. 
 
 
 
 
 
Figure 12: Active (basal tone) and passive (Ca2+ free) axial force for P-d curves at the high (z = 1.95) 
axial stretch setpoint for the wild-type and at the mid (z = 1.80) axial stretch setpoint for the mdx and 
sgcd-/- arteries. Comparing the results from these two different axial stretch setpoints allows us to see the 
change in diameter over pressurization for all three groups of vessels when stretched to ~1.05 of their in 
vivo axial stretch. The axial force values for the sgcd-/- are decreased but not significantly different from 
the wild-type in either the active or passive state (p < 0.05). mdx values are significantly decreased from 
the wild-type over low pressures in the active state and over a wide range of pressures (P = 2 – 116 
mmHg) in the passive state (indicated by *M). 
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 It also is possible that changes in the cross-linking of the ECM occur in the absence of 
the DGC, decreasing the load the ECM bears and consequently increasing the load on the 
vascular SMCs. When -dystroglycan, a component of the DGC, binds to laminin in the 
extracellular matrix, a mechanical link is formed. Further, this binding may induce laminin 
polymerization and formation of an organized extracellular network that leads to changes in 
cytoskeletal architecture9. Although 71 integrins, as mentioned earlier, can replicate the 
mechanical link between laminin and muscle cell cytoskeletons, and are upregulated in mdx and 
sgcd-/- mice, they may not be able to compensate for the role of -dystroglycan in initiating 
laminin binding and polymerization. As a result, the ECM will be weakened with the reduction 
in cross-linking, and axial stress on the vascular SMCs will be increased, thus causing growth 
and remodeling to a decreased in vivo axial stretch. Also, the actin reorganization and 
transmembrane signaling involved with the laminin polymerization process may be affected, 
causing altered mechanical properties of vascular SMCs that may cause a changed in vivo axial 
stretch ratio.  
 The results of our studies on the carotid arteries of mice lacking the genes that produce 
dystrophin or sarcoglycan-delta (proteins associated with human muscular dystrophies) show 
that the vascular system as well as the skeletal muscle is affected when these proteins are absent.  
Current muscular dystrophy research efforts are focused on providing a better and longer life for 
patients with muscular dystrophy. As DMD and other muscular dystrophy patients with better 
medical treatment live longer, there is concern that they may suffer from cardiovascular diseases 
such as hypertension and atherosclerosis that affect many aging Americans. They may require 
special medical treatment, though, if their vascular system has been altered in the absence of 
dystrophin or other DGC proteins. We have shown that the vascular systems of mice lacking an 
intact DGC undergo mechanical alterations, and smooth muscle cells that make up the vascular 
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system in humans with DMD and LGMD may also be subject to mechanical or structural 
changes. It is therefore constructive to continue to study the vasculature in the absence of 
dystrophin, sarcoglycan-delta, and other DGC components in order to understand how the vessel 
remodels to a new, functional state without the DGC. Understanding the mechanism of 
adaptation of blood vessels that lack the DGC should further our understanding of DMD and 
other muscular dystrophies, and may equip physicians to more effectively treat patients with 
these disorders.  
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CHAPTER III 
 
CONCLUSIONS AND RECOMMENDATIONS 
 
 
The results of our studies on the large arteries of mice lacking the genes that produce 
dystrophin or sarcoglycan-delta (proteins associated with human muscular dystrophies) show 
that the vascular system as well as the skeletal muscle is affected when these proteins are absent. 
Although at this point we can only speculate as to the mechanism for these mechanical 
differences in the vascular system, steps could be taken to obtain evidence to investigate some of 
our preliminary conclusions without conducting additional mechanical tests. First, we 
recommend that the tissue from the untested right carotid arteries or the mouse aortas be tested 
for content of relevant proteins such as utrophin and 71 and 51 integrins. The aortic segments 
from the three different mouse types have already been processed to be assayed on a micro-
array, and those results may further guide us to test for additional pertinent proteins. Second, we 
recommend that the frozen sections of the tested left carotid arteries be stained for visualization 
of the 71 and 51 integrins, but also for the presence and location of fibronectin and laminin. 
Also, we recommend that the sections be analyzed to determine the dimensions, especially the 
wall-thickness, of cross-sections for the different mouse types as a verification of the results we 
gathered by measuring the arteries in the device. It may be possible, too, to analyze the sections 
for collagen mass-fraction using birefringence, and this analysis would provide another piece of 
information to help us discern the biomechanical process that has taken place in the mdx and 
sgcd-/- carotid arteries.  
Once these tissue analyses have been conducted, we recommend testing of additional 
mdx and sgcd-/- arteries. One simple test that could be done is a measurement of the in vivo and 
ex vivo axial stretch ratio of the carotid arteries of all three types of mice. This could be done 
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crudely with calipers or more sophisticatedly with a computer-imaging system linked to a 
microscope. Although these measurements may not be a perfect reflection of the true in vivo 
axial stretch, as the surgery to visualize the arteries may introduce extra axial stretches, it could 
still lend evidence to either support or disprove our interpretation of the results. Another 
experiment that would be telling is culturing these arteries over a period of days to try to induce 
and measure vascular remodeling. Our results suggest that these arteries have remodeled 
significantly in response to increases in axial stress, and so it would be interesting to culture the 
arteries at increased and decreased axial stresses and observe the mechanical and molecular 
response. It would also be worthwhile to use the in vivo axial stretch values we inferred to set-up 
these arteries at conditions that accurately reflect their in vivo situation. Although our results did 
not show that these arteries had remodeled to adjust to circumferential or wall shear stresses, it is 
possible that the remodeling response of the arteries that lack an intact DGC to high pressure or 
high flow will be different than the normal response. In fact, previous acute studies have shown 
attenuated flow-induced dilation responses of mdx carotid arteries.28,30 Culturing both mdx and 
sgcd-/- arteries for two or more days in high pressure or high flow culture conditions would 
enable us to record any altered mechanical adaptation that occurs in the knockout vessels under 
increased circumferential and shear stresses. For these future experiments, another method could 
be employed to assess any changes in the orientation of elastin in the ECM. En face confocal 
microscopy has been used to visualize the internal elastic laminae, the layers of extracellular 
matrix that are present between vascular SMCs in arteries. In this method (described by Jackson 
et al.25 ), vessels are opened longitudinally and mounted for examination with a confocal 
microscope, as the internal elastic laminae possess natural autofluorescence and allow 
visualization of elastin and fenestrae present between the layers of vascular SMCs.  
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These recommended experiments would contribute to current muscular dystrophy 
research efforts that are focused on providing a better and longer life for patients with muscular 
dystrophy. As DMD and other muscular dystrophy patients with better medical treatment live 
longer, there is concern that they may suffer from cardiovascular diseases such as hypertension 
and atherosclerosis that affect many aging Americans. They may require special medical 
treatment, though, if their vascular system has been altered in the absence of dystrophin or other 
DGC proteins. We have shown that the vascular systems of mice lacking an intact DGC undergo 
mechanical alterations, and smooth muscle cells that make up the vascular system in humans 
with DMD and LGMD may also be subject to mechanical or structural changes. It is therefore 
constructive to continue to study the vasculature in the absence of dystrophin, sarcoglycan-delta, 
and other DGC components in order to understand how the vessel remodels to a new, functional 
state without the DGC. As we further our understanding of the mechanism of adaptation of blood 
vessels that lack the DGC, this should further our understanding of DMD and other muscular 
dystrophies, as well as vascular growth and remodeling principles. We hope that through these 
findings, we may equip physicians to more effectively treat patients with these muscular 
dystrophies and vascular diseases.  
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Figure 13: Active (basal tone) and passive (Ca2+ free) P-d curves at the low (z = 1.65) axial stretch 
setpoint. The mdx and sgcd-/- curves tend to diverge from the wild-type at high pressures in the active 
state, but at lower pressures in the passive state. Although trends are visible, there were no significant 
differences (p < 0.05) for this data.  
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Figure 14: Active (basal tone) and passive (Ca2+ free) P-d curves at the mid (z = 1.80) axial stretch 
setpoint. The mdx and sgcd-/- curves tend to diverge from the wild-type at mid-range pressures in both the 
active and passive states, although there were no significant differences (p < 0.05) for this data.  
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Figure 15: Active (basal tone) and passive (Ca2+ free) circumferential stress-stretch curves at the low (z = 
1.65) axial stretch setpoint. There was a range of circumferential stretch values (	 = 1.01 – 1.115) in the 
passive state, indicated by *M, for which the mdx circumferential stresses were significantly greater (p < 
0.05) than the wild-type values.  
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Figure 16: Active (basal tone) and passive (Ca2+ free) circumferential stress-stretch curves at the mid (z = 
1.80) axial stretch setpoint. There was a range of circumferential stretch values (	 = 0.935 – 1.025) in the 
active state and (	 = 0.980 – 0.140) in the passive state, indicated by *M, for which the mdx 
circumferential stresses were significantly greater (p < 0.05) than the wild-type values.  
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Figure 17: Passive axial force response during P-d test for all mouse types at all axial stretch setpoints. 
Mouse type (wt = wild-type) and axial stretch are indicated on the right axis where the curve ends. Note 
the disparity between the wild-type and knockout curves at the high axial stretch and the relative similarity 
between the wild-type curve at the high axial stretch (z =1.95) and the mdx and sgcd-/- curves at the mid 
axial stretch (z =1.8), just as we saw in the active axial force response. 
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Figure 18: Active (basal tone) and passive (Ca2+ free) axial f- curves at the low (P = 60 mmHg) pressure 
setpoint. Note that the axial force for the mdx and sgcd-/- tend to be greater than the wild-type at the 
higher axial stretches. The mdx values become significantly different (p < 0.05) from the wild-type at the 
axial stretch z = 1.95 in the active state and at z = 1.91 – 1.95 in the passive state (indicated by the 
*M). The sgcd-/- values are significantly different for the pressure range z = 1.81 – 1.95 in the active 
state and z = 1.77 – 1.95 in the passive state (indicated by the *S). 
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Figure 19: Active (basal tone) and passive (Ca2+ free) axial f- curves at the mid (P = 100 mmHg) 
pressure setpoint. Note that the axial force for the mdx and sgcd-/- tend to be greater than the wild-type. 
The mdx values become significantly different (p < 0.05) from the wild-type over the axial stretch range z 
= 1.85 – 1.95 in the active state and at z = 1.77 – 1.95 in the passive state (indicated by the *M). The 
sgcd-/- values are significantly different for the pressure range z = 1.91 – 1.95 in the active state and z = 
1.83 – 1.95 in the passive state (indicated by the *S). 
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Figure 20: Active (basal tone) and passive (Ca2+ free) axial f- curves at the high (P = 140 mmHg) 
pressure setpoint. Note that the axial force for the mdx and sgcd-/- are clearly greater than the wild-type. 
The mdx values become significantly different (p < 0.05) from the wild-type over the axial stretch range z 
= 1.75 – 1.95 in the active state and at z = 1.73 – 1.95 in the passive state (indicated by the *M). The 
sgcd-/- values are significantly different for the pressure range z = 1.81 – 1.95 in the active state and z = 
1.77 – 1.95 in the passive state (indicated by the *S). 
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Figure 21: Active (basal tone) and passive (Ca2+ free) axial stress-stretch curves at the low (P = 60 
mmHg) pressure setpoint. There were no significant differences in the active state. The mdx values 
become significantly different (p < 0.05) from the wild-type at the axial stretch z = 1.95 in the passive 
state (indicated by the *M).  
 
60 
 
A
x
ia
l S
tr
es
s 

z
(k
Pa
)
Wild-type mdx sgcd-/-
PASSIVEACTIVE
P = 100 mmHg
Axial Stretch z
1.15 1.35 1.55 1.951.751.15 1.35 1.55 1.951.75
*M
*S
0
100
200
300
400
500
600
700
*M
*S
 
 
Figure 22: Active (basal tone) and passive (Ca2+ free) axial stress-stretch curves at the mid (P = 100 
mmHg) pressure setpoint. The axial stresses for the mdx and sgcd-/- tend to be greater than the wild-type 
in both the active and passive state, but the significant differences are more evident in the passive state. 
The mdx values become significantly different (p < 0.05) from the wild-type over the axial extension range 
z = 1.89 – 1.95 in the active state and at z = 1.77 – 1.97 in the passive state (indicated by the *M). The 
sgcd-/- values are significantly different for the pressure range z = 1.93 – 1.97 in the active state and z = 
1.83 – 1.97 in the passive state (indicated by the *S). 
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Figure 23: Active (basal tone) and passive (Ca2+ free) axial f-curves, with the axial stretch normalized to 
the in vivo axial stretch, at the high (P = 140mmHg) pressure setpoint. The axial force values for the mdx 
and sgcd-/- are no longer significantly different from the wild-type in either the active and passive state (p 
< 0.05) when the axial stretch is normalized to the estimated in vivo axial stretch for each mouse type. 
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